TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38421757
Drug: Internet-based acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based acceptance and commitment therapy (iACT)
Study: 38421881
Drug: High ctDNA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High ctDNA levels evaluated by variant allele frequency (VAF) and haploid genome equivalents per milliliter of plasma (hGE/mL) at baseline
Study: 38421921
Drug: Valbenazine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine (both doses)
Study: 38422496
Drug: Antibiotics (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (25 mg/kg cefazolin IV up to 1g or clindamycin 10 mg/kg up to 600 mg IV in case of cefazolin allergy)
Study: 38422496
Drug: Placebo (10-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10-mL prefilled syringe of normal saline)
Study: 38422585
Drug: CBP501 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBP501 16 mg/m, cisplatin, nivolumab
Study: 38422585
Drug: CBP501 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBP501 25 mg/m, cisplatin, nivolumab
Study: 38422585
Drug: CBP501 (unknown
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBP501 (unknown dosage), cisplatin, nivolumab
Study: 38423021
Drug: BCG-Denmark vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-Denmark vaccination (0.1 mL intradermal injection)
Study: 38423021
Drug: Placebo (intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intradermal injection of 0.9% saline)
Study: 38423051
Drug: Pivekimab sunirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivekimab sunirine at 0.045 mg/kg once every 3 weeks (recommended phase 2 dose)
Study: 38423051
Drug: Pivekimab sunirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivekimab sunirine at doses of 0.015 mg/kg to 0.450 mg/kg (schedule A)
Study: 38423215
Drug: Low-dose cotoretigene
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cotoretigene toliparvovec (5 × 10^11 vg/mL)
Study: 38423215
Drug: High-dose cotoretigene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cotoretigene toliparvovec (5 × 10^12 vg/mL)
Study: 38423215
Drug: Low-dose cotoretigene
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cotoretigene toliparvovec
Study: 38423215
Drug: High-dose cotoretigene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cotoretigene toliparvovec
Study: 38423758
Drug: Intervention: TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: TNF inhibitors (TNFi) as a time-varying covariate
Study: 38423765
Drug: Intravenous thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous thiamine (200 mg in 50 mL 0.9% saline)
Study: 38423770
Drug: Intensive glycaemic
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive glycaemic targets (fasting <90 mg/dL and 1-hour postprandial <120 mg/dL)
Study: 38423770
Drug: Standard glycaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glycaemic targets (fasting <95 mg/dL and 1-hour postprandial <140 mg/dL)
Study: 38423866
Drug: Niraparib 1
Normalized name: niraparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 1 × 300-mg tablet
Study: 38423866
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 100-mg capsules
Study: 38423866
Drug: Niraparib 1
Normalized name: niraparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 1 × 300-mg tablet in fed state (high-fat meal)
Study: 38423866
Drug: Niraparib 1
Normalized name: niraparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 1 × 300-mg tablet in fasted state
Study: 38423992
Drug: Avacopan 30
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avacopan 30 or 60 mg twice daily
Study: 38423992
Drug: Avacopan co-administered
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avacopan co-administered with itraconazole
Study: 38423992
Drug: Avacopan co-administered
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avacopan co-administered with rifampin
Study: 38424308
Drug: Encorafenib (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib (450 mg QD) and binimetinib (45 mg BID)
Study: 38424308
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg) and Bupropion (75 mg)
Study: 38424308
Drug: Encorafenib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib (300 mg QD) and cetuximab (400 mg/m2)
Study: 38424537
Drug: Vortioxetine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (5-20 mg, n=73)
Study: 38424609
Drug: Integrated exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated exercise intervention (16-week group-based, workouts twice a week, endurance and resistance training)
Study: 38425141
Drug: Oral megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral megestrol acetate (MA) 160 mg
Study: 38425284
Drug: Adjunctive brexpiprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brexpiprazole 0.5-2 mg/day
Study: 38425504
Drug: Carboplatin (AUC5)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (AUC5) administered intravenously every 21 days for 6-9 cycles
Study: 38425987
Drug: Irinotecan (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (180 mg/m2) administered in 28-day cycles
Study: 38426909
Drug: Fully Closed-Loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully Closed-Loop Insulin Delivery
Study: 38427076
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion during a hyperinsulinaemic-euglycaemic clamp in participants with type 1 diabetes
Study: 38427076
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion during a hyperinsulinaemic-euglycaemic clamp in healthy participants
Study: 38427322
Drug: Combination A
Normalized name: SUNFLOWER OIL 7.92 g in 14 g TOPICAL STICK [OrgaPlus Super Care Balm for combination and oi ly skin type 14g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination A (flexible single-channel EEG headband + actigraphy)
Study: 38427322
Drug: Combination B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination B (rigid single-channel EEG headband + actigraphy)
Study: 38428259
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg oral dose
Study: 38428265
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (Pemetrexed Cisplatin)
Study: 38428265
Drug: Personalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized treatment based on EGFR mutation (Erlotinib) and ERCC1 expression
Study: 38428428
Drug: Idebenone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone treatment (900 mg/day) for 24 months
Study: 38428681
Drug: Salvage stereotactic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage stereotactic body radiation therapy (SBRT) at 42.5 Gy in 5 fractions
Study: 38428681
Drug: Salvage stereotactic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage stereotactic body radiation therapy (SBRT) at 40 Gy (DL1)
Study: 38428681
Drug: Salvage stereotactic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage stereotactic body radiation therapy (SBRT) at 42.5 Gy (DL2)
Study: 38428681
Drug: Salvage stereotactic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage stereotactic body radiation therapy (SBRT)
Study: 38429253
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg twice daily)
Study: 38430272
Drug: Mogamulizumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab (0.3 mg/kg intravenous every 12 weeks)
Study: 38430375
Drug: Durvalumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab monotherapy and durvalumab plus tremelimumab
Study: 38431131
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of hydrocortisone parenterally every 8 hours for 3 days
Study: 38431131
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of hydrocortisone
Study: 38431133
Drug: Tailored medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored medication adherence-promotion intervention
Study: 38431156
Drug: AZD1222 (ChAdOx1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1222 (ChAdOx1 nCov-19) two-dose primary series
Study: 38431445
Drug: Hemin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemin (4 mg/kg)
Study: 38431766
Drug: Systemic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic or topical interventions (specifics not provided)
Study: 38432233
Drug: Tebipenem pivoxil
Normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebipenem pivoxil hydrobromide (600 mg orally every 8 h)
Study: 38432233
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (500 mg amoxicillin and 125 mg clavulanic acid orally every 8 h)
Study: 38432247
Drug: Cetuximab 500
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 500 mg/m2
Study: 38432714
Drug: Prenatal supplementation
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal supplementation (daily oral multiple micronutrient supplementation including 50 μg/d of vitamin B-12)
Study: 38432714
Drug: Postnatal supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postnatal supplementation (postnatal supplement including 50 μg/d of vitamin B-12)
Study: 38433191
Drug: 5-FU (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (200 µg/ml) and LMWH (5 IU/ml)
Study: 38433842
Drug: H56:IC31 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H56:IC31 vaccine (5 micrograms, administered intramuscularly at day 84 and day 140)
Study: 38433842
Drug: H56:IC31 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H56:IC31 vaccine
Study: 38433842
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard TB treatment only)
Study: 38434639
Drug: Lactoferrin (Lf)
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin (Lf) in oral nutritional supplements (ONS)
Study: 38435429
Drug: Pharmacy Integrated
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacy Integrated Community Care (PICC) program - a structured, four-session group-based program guided by experienced pharmacists focusing on medication adherence and diabetes management.
Study: 38435809
Drug: Opioid-free anaesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-free anaesthesia (sevoflurane-dexmedetomidine with continuous infusion of lidocaine and ketamine)
Study: 38435809
Drug: Opioid-based anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-based anaesthesia (sevoflurane-remifentanil with morphine transition)
Study: 38435944
Drug: Postoperative hyperamylasemia
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative hyperamylasemia (POH) defined as serum amylase >100 U/L on postoperative day 1 (POD1)
Study: 38435944
Drug: Blood loss
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood loss >350 mL, pancreatic duct size <3 mm, elevated POD1 serum amylase >100 U/L
Study: 38435978
Drug: Web-based EMDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based EMDR intervention (up to 12 sessions, delivered twice weekly)
Study: 38436365
Drug: One-month dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-month dual antiplatelet therapy (DAPT) with ticagrelor and aspirin
Study: 38436463
Drug: Delpazolid 800
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 800 mg once a day for 14 days
Study: 38436463
Drug: Delpazolid 400
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 400 mg twice a day for 14 days
Study: 38436463
Drug: Delpazolid 800
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 800 mg twice a day for 14 days
Study: 38436463
Drug: Delpazolid 1200
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 1200 mg once a day for 14 days
Study: 38436495
Drug: Intranasal nalmefene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nalmefene (2.7 mg)
Study: 38436924
Drug: Regular-strength dual-action
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-strength dual-action tablets (RS-DAT) - niraparib 200 mg/AA 1000 mg once daily
Study: 38436924
Drug: Lower-strength dual-action
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-strength dual-action tablets (LS-DAT) - niraparib 100 mg/AA 500 mg
Study: 38436924
Drug: Single-agent combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent combination (SAC) - abiraterone acetate alone
Study: 38436947
Drug: Silver Diamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver Diamine Fluoride (SDF) 38% concentration solution
Study: 38436947
Drug: Sealants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealants with Atraumatic Restorative Treatment (ART)
Study: 38436998
Drug: Batoclimab (680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batoclimab (680 mg, subcutaneous injections, 6 weekly doses)
Study: 38436998
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, 6 weekly doses)
Study: 38437725
Drug: CD19-CD28 in
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-CD28 in combination with glofitamab
Study: 38437725
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of glofitamab with CD19-CD28 and CD19-4-1BBL
Study: 38437868
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of aldosterone
Study: 38438123
Drug: RTS,S full-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S full-dose regimen (2 full doses at months 0 and 1)
Study: 38438123
Drug: RTS,S fractional-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S fractional-dose regimen (one-fifth doses)
Study: 38438123
Drug: RTS,S full-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S full-dose regimen (R012-14-26)
Study: 38438123
Drug: RTS,S fractional-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S fractional-dose regimen (Fx012-14-26)
Study: 38438123
Drug: RTS,S fractional-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S fractional-dose regimen (Fx017-20-32)
Study: 38438427
Drug: PTX-COVID19-B vaccine
Normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX-COVID19-B vaccine candidate (40 μg, two doses administered 28 days apart)
Study: 38438427
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (30 μg, two doses administered 21 days apart)
Study: 38438427
Drug: PTX-COVID19-B vaccine
Normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX-COVID19-B vaccine candidate
Study: 38438681
Drug: 10.5 mg
Normalized name: pectin 10.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 mg bupivacaine
Study: 38438681
Drug: 11.25 mg
Normalized name: phentermine 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 mg bupivacaine
Study: 38438681
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg bupivacaine
Study: 38438681
Drug: 9.75 mg
Normalized name: sulfur 9.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.75 mg bupivacaine
Study: 38438923
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg roflumilast
Study: 38438923
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg roflumilast
Study: 38439027
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) 0.1~1.0 μg/kg/h for 24 h
Study: 38439092
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy Enhanced (CBT-E)
Study: 38440130
Drug: OC-01 (varenicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 (varenicline solution) nasal spray 0.6 mg/mL twice daily (BID)
Study: 38440130
Drug: OC-01 (varenicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 (varenicline solution) nasal spray 0.6 mg/mL BID
Study: 38440130
Drug: Vehicle nasal
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle nasal spray
Study: 38440179
Drug: Houtou Jianweiling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Houtou Jianweiling tablet
Study: 38440302
Drug: Super-bioavailability itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Super-bioavailability itraconazole (SUBA-itra)
Study: 38440406
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) intervention
Study: 38441576
Drug: Enfortumab Vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enfortumab Vedotin (EV) 1.25 mg/kg plus Pembrolizumab 200 mg
Study: 38441657
Drug: Laparoscopic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic and open surgery for rectal cancer (part of COLOR II trial)
Study: 38441850
Drug: AbGn-107 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbGn-107 at 1.0 mg/kg every 2 weeks (Q2W)
Study: 38441854
Drug: 12 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg/day cannabidiol (Epidyolex)
Study: 38441919
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 2.5 mg + 100 mg placebo
Study: 38441919
Drug: Modafinil 100
Normalized name: modafinil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 100 mg + 2.5 mg placebo
Study: 38441919
Drug: Placebo 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2.5 mg + 100 mg placebo
Study: 38441919
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (combined with all interventions)
Study: 38442717
Drug: High-dose rivaroxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rivaroxaban regimen (HDRR, 20/15 mg)
Study: 38442717
Drug: Low-dose rivaroxaban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rivaroxaban regimen (LDRR, 15/10 mg)
Study: 38443077
Drug: Survey measuring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey measuring the impact of the cardiac condition on specific life domains (e.g., daily activities, social and family relationships, hobbies, sexual life)
Study: 38443081
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus daily mobile phone text messages with instructions for outdoor walking and functional leg exercises.
Study: 38443333
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg orally, twice daily), Bevacizumab biosimilar FKB238 (15 mg/kg intravenously, once every 3 weeks), Durvalumab (1.12 g intravenously, once every 3 weeks)
Study: 38443354
Drug: Antidepressant monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant monotherapy for 8 weeks
Study: 38443879
Drug: 2.9 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.9 mm Narrow Diameter Implants (Ti-Zr alloy)
Study: 38443879
Drug: 3.3 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.3 mm Control Group Implants
Study: 38443957
Drug: Self-administered at-home
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered at-home lung ultrasound (SAAH-LUS) with remote teleguidance
Study: 38443989
Drug: Fluoridated bottled
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated bottled water (0.7 mg/L F)
Study: 38444034
Drug: MTX combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX combined with TNF-α blocker certolizumab pegol (arm CZP)
Study: 38444034
Drug: MTX combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX combined with IL-6R blocker tocilizumab (arm TCZ)
Study: 38444064
Drug: Oral probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotics (5 billion colony-forming units each)
Study: 38444312
Drug: Hybrid-closed loop
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid-closed loop (HCL) therapy from diagnosis of T1D
Study: 38444429
Drug: CD19-CAR-DNT cells
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-CAR-DNT cells (RJMty19) at dose level 1 (DL1)
Study: 38444429
Drug: CD19-CAR-DNT cells
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-CAR-DNT cells (RJMty19) at dose level 3 (DL3)